Leukaemia, which may be acute or chronic, is a cancer that originates in blood-forming tissue such as the bone marrow, leading to the over-production of abnormal white blood cells. These abnormal cells accumulate more quickly in acute leukaemia, which is more aggressive than chronic leukaemia.
Lymphocytes and myeloid cells are the two main white blood cell types affected in leukaemia, leading to four leukaemia manifestations including acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL). Symptoms vary depending on subtype and can include weakness, increased rates of infection and general feeling of illness.
Diagnosis may involve blood testing, bone marrow biopsy, spinal tap and imaging tests (for example, CT, MRI and PET scans). The subsequent treatment will depend on the type of leukaemia and how far it has spread. Treatments may include radiation therapy, chemotherapy, biologic therapy, immunotherapy, targeted therapy and haematopoietic stem cell transplantation.
Related news and insights
AbbVie announced the publication of results from the Phase III VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM). The study, which evaluated newly-diagnosed AML patients who had not yet been treated and were unable to tolerate traditional intensive chemotherapy, found that Venclexta (venetoclax) in combination with Vidaza (azacitidin
Pfizer announced that the European Commission approved Daurismo (glasdegib), a Hedgehog pathway inhibitor, in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly diagnosed (de novo or secondary) acute myeloid leukemia (AML) in adult patients who are not candidates for standard chemotherapy.
Genentech, a member of the Roche Group announced positive results from the Phase III VIALE-A study, evaluating Venclexta (venetoclax) in combination with azacitidine in people with previously untreated acute myeloid leukemia (AML) who were ineligible for intensive induction chemotherapy.
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.
In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...
You may be interested in...
ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.
International Conference on Nephrology and Urology
ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.
18th Meeting of the EAU Section of Oncological Urology
ESOU21 will take place in conjunction with the meeting of the EAU Section of Urological Research (ESUR). Thus it will be an opportunity to have collaborative sessions and knowledge exchange with our colleagues from this prestigious office of the EAU.